Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of Pradigastat in Familial Chylomicronemia Syndrome
2012-000802-32Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pradigastat in primary chylomicronemia (FCS), sponsored by Novartis. Primary endpoint: Number of patients with adverse and serious adverse events. Started Jul 2012; status: completed.
02
Drugs
pradigastat
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on 2012-000802-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000802-32.